

Gilles DULUC

Directeur de la Recherche Clinique
et de l'Innovation

Talence, le 13/05/2025

Jeanne PATARD

Directrice adjointe de la Recherche
Clinique et de l'Innovation

Département Promotion Interne

Anne GIMBERT

Responsable
Tél 05.57.82.04.34
anne.gimbert@chu-bordeaux.fr

Object : Interventional Clinical Trial's results posting to the European Clinical Trial register (EudraCT) of the European Medicines Agency (EMA).

In accordance of Directive 2001/20/CE

Study Title : ANDDROID : Effect of intra-venous ocytocine injection after fetal expulsion in management of third-stage of labor after second trimester medical pregnancy termination

EudraCT Nbr : 2016-003143-11

Sponsor Nbr : CHUBX2016/20 / **ANSM Nbr** : 160702A-22

Transitioned study to the Regulation (EU) 536/2014 : no

Status of the study : prematurely ended

The number of patients recruited was under the threshold allowing the statistict analyse (27 patients included out of the 114 planned). No valorization was possible.

For the Head of the University Hospital of Bordeaux
and by delegation,
The Director of the Clinical research and Innovation

Gilles DULUC

par délégation, Jeanne Patard, directrice adjointe



DIRECTION GENERALE
12, rue Dubernat - 33404 Talence Cedex - Tél 05 56 79 56 79
www.chu-bordeaux.fr